Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN)
Metastatic and/or Recurrent Disease
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR WAN ZAMANIAH
wzamaniah@ummc.edu.my
CONTACT
SC: Cryst Sari: 03-79492120 (Research Room)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR WONG YOKE FUI
florencefui@yahoo.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Dr A phase III, multi-center, randomised (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemo-therapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O) Site
Hospital Wanita dan Kanak-kanak Sabah
PRINCIPAL INVESTIGATOR
Dr Suguna A/P Subramaniam
CONTACT
Roslin Guadih (016-8151234)